288 related articles for article (PubMed ID: 36729113)
1. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Casado I; Navascués A; Burgui C; Ezpeleta C; Castilla J; Guevara M; ;
Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729113
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Feb; 11(2):176-187. PubMed ID: 36216013
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada.
Carazo S; Skowronski DM; Brisson M; Sauvageau C; Brousseau N; Fafard J; Gilca R; Talbot D; Ouakki M; Febriani Y; Deceuninck G; De Wals P; De Serres G
Lancet Healthy Longev; 2023 Aug; 4(8):e409-e420. PubMed ID: 37459879
[TBL] [Abstract][Full Text] [Related]
7. Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.
He X; Liao Y; Liang Y; Yu J; Gao W; Wan J; Liao Y; Su J; Zou X; Tang S
Front Immunol; 2023; 14():1290279. PubMed ID: 38259438
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
[TBL] [Abstract][Full Text] [Related]
9. Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination.
Varea-Jiménez E; Aznar Cano E; Vega-Piris L; Martínez Sánchez EV; Mazagatos C; García San Miguel Rodríguez-Alarcón L; Casas I; Sierra Moros MJ; Iglesias-Caballero M; Vazquez-Morón S; Larrauri A; Monge S;
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Apr; 42(4):187-194. PubMed ID: 36737369
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of vaccination for preventing hospitalisation with COVID-19 in regional Queensland: a data linkage study.
Smoll NR; Al Imam MH; Shulz C; Booy R; Khandaker G
Med J Aust; 2023 Aug; 219(4):162-165. PubMed ID: 37400415
[TBL] [Abstract][Full Text] [Related]
12. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
[TBL] [Abstract][Full Text] [Related]
14. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.
Bager P; Wohlfahrt J; Bhatt S; Stegger M; Legarth R; Møller CH; Skov RL; Valentiner-Branth P; Voldstedlund M; Fischer TK; Simonsen L; Kirkby NS; Thomsen MK; Spiess K; Marving E; Larsen NB; Lillebaek T; Ullum H; Mølbak K; Krause TG;
Lancet Infect Dis; 2022 Jul; 22(7):967-976. PubMed ID: 35468331
[TBL] [Abstract][Full Text] [Related]
15. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.
Havers FP; Patel K; Whitaker M; Milucky J; Reingold A; Armistead I; Meek J; Anderson EJ; Weigel A; Reeg L; Seys S; Ropp SL; Spina N; Felsen CB; Moran NE; Sutton M; Talbot HK; George A; Taylor CA;
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(34):1085-1091. PubMed ID: 36006841
[TBL] [Abstract][Full Text] [Related]
16. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
Nordström P; Ballin M; Nordström A
PLoS Med; 2023 Feb; 20(2):e1004127. PubMed ID: 36802397
[TBL] [Abstract][Full Text] [Related]
19. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
20. Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Clin Microbiol Infect; 2023 Jan; 29(1):101-106. PubMed ID: 36028091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
